CLN3 and glycogen storage disease VI: Similar to ASO-16, ASO-29a induces robust, long-lasting exon 5 skipping for up to 6 months in the retina, demonstrating the activity of a potential clinically relevant ASO for treating CLN3 Batten disease vision loss in humans.